Researchers from the National University of Singapore (NUS) have made a groundbreaking discovery that could potentially revolutionize fertility treatments for older women. A team from the Mechanobiology Institute (MBI) and the NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality (ACRLE) has developed an innovative technique to enhance the reproductive potential of aged oocytes, or immature egg cells. The study, published in…
Cartherics, an Australian biotech company developing immune cell therapies, has announced the successful completion of an oversubscribed private financing round, raising over AU$15 million. This funding will primarily support the clinical trial of CTH-401, the company’s lead cell therapy for ovarian cancer, and expand its pipeline to include other diseases. Based in Melbourne, Cartherics focuses on developing cell-based immunotherapies for cancer treatment.…
Axena Health, a medical device company specializing in female pelvic health, has announced that its Leva Pelvic Health System will be included in a significant clinical study funded by the National Institutes of Health’s (NIH) Pelvic Floor Disorders Network (PFDN). The study, titled “Training for Urinary Leakage Improvement after Pregnancy” (TULIP), aims to compare three first-line treatments for postpartum urinary incontinence (UI).…
YourChoice Therapeutics, a San Francisco-based biopharmaceutical company, has announced the commencement of its second human study for YCT-529, a hormone-free male birth control pill. The company has dosed its first cohort of male volunteers in a phase 1b/2a clinical study, following the successful completion of a phase 1a study that demonstrated the drug candidate’s safety for use in men. The phase 1b/2a…
Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Kisqali (ribociclib) for a new indication in early breast cancer. This approval marks a significant development in breast cancer treatment, particularly for women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer. The FDA has approved Kisqali in combination with an aromatase inhibitor for adjuvant…
Almond, a tech-enabled OBGYN practice in Los Angeles, is set to introduce its Group Pregnancy Care service. This launch aims to improve maternal health outcomes amidst the ongoing maternal mortality crisis in the United States, which has the highest rate of maternal mortality among high-income nations. The new Group Pregnancy Care model offers a collaborative approach to prenatal care, which has been…
University of Iowa Health Care and UK-based Naitive Technologies have initiated a joint project to evaluate the diagnostic accuracy of OsteoSight, an FDA-designated breakthrough medical device. This device is designed to identify individuals at risk of low bone mineral density (BMD) using X-rays taken for other medical purposes. The project aims to enhance the early detection of osteoporosis, a condition affecting millions…
Joylux and Respin, the midlife wellness brand founded by actress Halle Berry, have announced a partnership aimed at addressing intimate health issues faced by peri/post-menopausal women. This collaboration introduces two new products: an intimacy gel named LET’S SPIN and a special edition of the vFit Plus device. The partnership responds to the needs of the estimated 60 million women in the U.S.…
